Migraine treatment with gene-related peptides

Gene-related peptides or monoclonal antibodies are a reliable, efficient, and secure method of managing migraines for many patients. In addition, they can help control the frequency and intensity of migraines, relieving pain. Monoclonal antibodies are specific substances produced by the immune system. A cell, a molecule — an antigen — is attacked by antibodies to neutralize or destroy. For example, the protein CGRP (Calcitonin gene-related peptide), formed in the body, is responsible for pain during migraine attacks. It triggers a nerve impulse that provokes these sensations. The higher its concentration, the more robust, painful, and prolonged the pain attack. The principle of operation of the drugs is common – to interrupt the "path of pain" with the participation of the CGRP protein. They either block the CGRP protein itself with Fremanezumab, Galkanezumab, and Eptinezumab or the action of CGRP on its receptor (a special zone on the cell surface) with Erenumab. The doctor will select an appropriate medication based on the features of each case. The task of migraine therapy is to take illness under control and make it rare, responding well to treatment with painkillers. Usually, medicine is prescribed for 6 or 12 months. This period is usually enough to "reboot" the brain, after which there will be fewer attacks, or they will disappear altogether.